Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RMS2
MCID: RHB024
MIFTS: 67

Rhabdomyosarcoma 2 (RMS2)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Rhabdomyosarcoma 2

About this section

MalaCards integrated aliases for Rhabdomyosarcoma 2:

Name: Rhabdomyosarcoma 2 56 73
Alveolar Rhabdomyosarcoma 12 52 58 29 6 15 17 71
Rhabdomyosarcoma Alveolar 52 73 54 39
Rhabdomyosarcoma, Alveolar 56 74 43
Alveolar Childhood Rhabdomyosarcoma 12 71
Rhabdomyosarcoma 2, Alveolar 56 13
Rms2 56 73
Rmsa 56 73
Rhabdomyosarcoma, Alveolar; Rmsa 56
Arms 52

Characteristics:

OMIM:

56
Inheritance:
somatic mutation


HPO:

31
rhabdomyosarcoma 2:
Inheritance autosomal recessive inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Muscle diseases Neuronal diseases Bone diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4051
OMIM 56 268220
MeSH 43 D018232
NCIt 49 C3749 C7958
SNOMED-CT 67 404053004 63449009
MESH via Orphanet 44 D018232
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0206655
Orphanet 58 ORPHA99756
MedGen 41 C0206655
SNOMED-CT via HPO 68 124975008 258211005
UMLS 71 C0206655 C0279613
Sources

Summaries for Rhabdomyosarcoma 2

About this section
UniProtKB/Swiss-Prot : 73 Rhabdomyosarcoma 2: A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

MalaCards based summary : Rhabdomyosarcoma 2, also known as alveolar rhabdomyosarcoma, is related to breast rhabdomyosarcoma and soft tissue sarcoma. An important gene associated with Rhabdomyosarcoma 2 is PAX3 (Paired Box 3), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Formaldehyde and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and prostate, and related phenotypes are alveolar rhabdomyosarcoma and cellular

Wikipedia : 74 Alveolar rhabdomyosarcoma (ARMS) is a sub-type of the rhabdomyosarcoma soft tissue cancer family whose... more...

More information from OMIM: 268220
Sources

Related Diseases for Rhabdomyosarcoma 2

About this section

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 breast rhabdomyosarcoma 31.1 PAX3 MYOG MYOD1 MB
2 soft tissue sarcoma 31.0 MDM2 FOXO1 EWSR1
3 rare tumor 31.0 EWSR1 DES
4 orbit rhabdomyosarcoma 31.0 PAX3 MYOG MB
5 spindle cell sarcoma 31.0 MYOG MDM2 DES
6 prostate rhabdomyosarcoma 31.0 MYOG MYOD1
7 desmoplastic small round cell tumor 30.9 WT1 EWSR1 DES
8 skeletal muscle neoplasm 30.9 RHD MYOG MYOD1 MB
9 small cell carcinoma 30.9 WT1 MYCN ENO2 ALK
10 familial retinoblastoma 30.9 RB1 MDM2 CDK4
11 osteogenic sarcoma 30.8 WT1 RB1 MDM2 IGF1R CDK4
12 beckwith-wiedemann syndrome 30.7 WT1 TH PAX7 MYOD1 IGF1R
13 pleomorphic rhabdomyosarcoma 30.7 PAX7 PAX3 MYOG MYOD1 MB FOXO1
14 waardenburg's syndrome 30.7 PAX7 PAX3 MYOD1
15 chondrosarcoma 30.7 MDM2 EWSR1 ENO2 CDK4
16 cellular myxoid liposarcoma 30.6 MDM2 EWSR1 CDK4
17 olfactory neuroblastoma 30.6 MB EWSR1 ENO2
18 mesenchymal chondrosarcoma 30.6 MYOG MYOD1 ENO2 DES
19 botryoid rhabdomyosarcoma 30.5 PAX3 MYOG MYOD1 MB DES
20 merkel cell carcinoma 30.5 RB1 ENO2 ALK
21 connective tissue benign neoplasm 30.5 MDM2 EWSR1 ENO2 CDK4
22 retinoblastoma 30.5 RB1 MYOD1 MYCN MDM2 ENO2 CDK4
23 malignant mesenchymoma 30.5 MYOG MYOD1 MDM2 MB DES
24 alveolar soft part sarcoma 30.4 MYOG MYOD1 MB EWSR1 ENO2 DES
25 gliosarcoma 30.4 RB1 MDM2 ENO2 CDK4
26 leukemia, acute lymphoblastic 30.4 WT1 RB1 MYCN MDM2 CDK4
27 fibrous histiocytoma 30.3 MYOG EWSR1 ENO2 DES ALK
28 malignant fibrous histiocytoma 30.3 MYOG MYOD1 MDM2 MB EWSR1 DES
29 glioblastoma multiforme 30.2 RB1 MYCN MDM2 IGF1R FOXO1 CDK4
30 neuroblastoma 30.1 TH RB1 MYCN MDM2 IGF1R EWSR1
31 wilms tumor 1 30.1 WT1 PAX3 MYOG MYCN IGF1R EWSR1
32 liposarcoma 30.1 RB1 MYOG MDM2 MB IGF1R EWSR1
33 leiomyosarcoma 29.9 WT1 RB1 MYOG MDM2 MB ENO2
34 sarcoma, synovial 29.9 WT1 PAX3 MYOG MYCN MDM2 IGF1R
35 sarcoma 29.8 WT1 RB1 MYOG MYOD1 MDM2 IGF1R
36 leukemia, acute myeloid 29.8 WT1 MYCN MDM2 IGF1R FOXO1 EWSR1
37 embryonal rhabdomyosarcoma 29.7 PAX7 PAX3 MYOG MYOD1 MYCN MDM2
38 ewing sarcoma 29.7 WT1 PAX7 PAX3 MYOG MYCN MDM2
39 muscle cancer 29.4 WT1 RMST RHD PAX7 PAX3 MYOG
40 skeletal muscle cancer 29.3 WT1 RMST RHD PAX7 PAX3 MYOG
41 rhabdomyosarcoma 28.8 WT1 RMST RB1 PAX7 PAX3 MYOG
42 mixed type rhabdomyosarcoma 11.4
43 orbit alveolar rhabdomyosarcoma 11.4
44 central nervous system rhabdomyosarcoma 10.7 PAX3 FOXO1
45 myoblastoma 10.7 MYOG ENO2
46 clear cell basal cell carcinoma 10.7 PAX7 PAX3 MYOG
47 ring chromosome 7 10.7 MDM2 CDK4
48 conventional leiomyosarcoma 10.7 PAX7 MYOG MYOD1
49 spermatic cord cancer 10.6 WT1 MYOD1
50 mediastinum liposarcoma 10.6 MDM2 CDK4

Graphical network of the top 20 diseases related to Rhabdomyosarcoma 2:



Diseases related to Rhabdomyosarcoma 2
Sources

Symptoms & Phenotypes for Rhabdomyosarcoma 2

About this section

Human phenotypes related to Rhabdomyosarcoma 2:

31
# Description HPO Frequency HPO Source Accession
1 alveolar rhabdomyosarcoma 31 HP:0006779

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
alveolar rhabdomyosarcoma

Clinical features from OMIM:

268220

MGI Mouse Phenotypes related to Rhabdomyosarcoma 2:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 CDK4 DES DIABLO ENO2 FOXO1 IGF1R
2 behavior/neurological MP:0005386 10.45 ALK CDK4 DES DIABLO ENO2 FOXO1
3 growth/size/body region MP:0005378 10.45 ALK CDK4 DIABLO ENO2 FOXO1 IGF1R
4 homeostasis/metabolism MP:0005376 10.43 ALK CDK4 DES FOXO1 IGF1R MB
5 cardiovascular system MP:0005385 10.38 CDK4 DES FOXO1 IGF1R MB MDM2
6 mortality/aging MP:0010768 10.35 ALK CDK4 DES FOXO1 IGF1R MB
7 embryo MP:0005380 10.31 CDK4 FOXO1 IGF1R MB MDM2 MYCN
8 hematopoietic system MP:0005397 10.28 CDK4 FOXO1 IGF1R MB MDM2 MYCN
9 muscle MP:0005369 10.27 CDK4 DES FOXO1 IGF1R MB MDM2
10 endocrine/exocrine gland MP:0005379 10.26 ALK CDK4 FOXO1 IGF1R MDM2 PAX3
11 craniofacial MP:0005382 10.24 CDK4 ENO2 FOXO1 IGF1R MDM2 MYCN
12 integument MP:0010771 10.21 ALK CDK4 FOXO1 IGF1R MDM2 MYOG
13 digestive/alimentary MP:0005381 10.18 CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
14 neoplasm MP:0002006 10.17 ALK CDK4 FOXO1 IGF1R MDM2 MYOD1
15 liver/biliary system MP:0005370 10.15 CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
16 nervous system MP:0003631 10.14 ALK CDK4 ENO2 FOXO1 IGF1R MDM2
17 normal MP:0002873 10.1 CDK4 DIABLO FOXO1 MDM2 MYCN MYOD1
18 no phenotypic analysis MP:0003012 10.07 FOXO1 MDM2 MYCN MYOD1 MYOG PAX3
19 reproductive system MP:0005389 9.81 ALK CDK4 FOXO1 IGF1R MDM2 MYCN
20 respiratory system MP:0005388 9.73 ALK ENO2 IGF1R MB MYCN MYOD1
21 pigmentation MP:0001186 9.65 ALK CDK4 MDM2 PAX3 RB1
22 skeleton MP:0005390 9.36 ALK CDK4 FOXO1 IGF1R MDM2 MYCN
Sources

Drugs & Therapeutics for Rhabdomyosarcoma 2

About this section

Drugs for Rhabdomyosarcoma 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1663)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
2
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
3
Vorapaxar Approved Phase 4 618385-01-6
4
Losartan Approved Phase 4 114798-26-4 3961
5
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
6
Ethambutol Approved Phase 4 74-55-5 3279 14052
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Menthol Approved Phase 4 2216-51-5 16666
9
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
10
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
11
Probucol Approved, Investigational Phase 4 23288-49-5 4912
12
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
13
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
14
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
15
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 298 5959
16
Rimonabant Approved, Investigational Phase 4 158681-13-1, 168273-06-1 104850
17
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
18
Clonidine Approved Phase 4 4205-90-7 2803
19
Nadolol Approved Phase 4 42200-33-9 39147
20
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
21
Lacidipine Approved, Investigational Phase 4 103890-78-4
22 Tangerine Approved Phase 4
23
Ticlopidine Approved Phase 4 55142-85-3 5472
24
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
25
Cetirizine Approved Phase 4 83881-51-0 2678
26
Azelastine Approved Phase 4 58581-89-8 2267
27
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
28
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
29
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
30
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
31
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
32
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
33
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
34
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
35
Fenofibrate Approved Phase 4 49562-28-9 3339
36
Insulin lispro Approved Phase 4 133107-64-9
37
Licorice Approved Phase 4
38
Ezetimibe Approved Phase 4 163222-33-1 150311
39
Fosamprenavir Approved Phase 4 226700-79-4 131536
40
Misoprostol Approved Phase 4 59122-46-2 5282381
41
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
42
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
43
Lithium carbonate Approved Phase 4 554-13-2
44
Interferon beta-1b Approved Phase 4 145155-23-3
45
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
46
Sulfamethoxazole Approved Phase 4 723-46-6 5329
47
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
48
Ganirelix Approved Phase 4 123246-29-7, 124904-93-4 25081094
49
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
50
Luliconazole Approved Phase 4 187164-19-8

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
2 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
3 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
4 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
5 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
6 Assessment of Implantation Potential of Embryos Cultured by Time-lapse Technology (Embryoscope) Before Transfer in In-vitro Fertilization (IVF) / Intracytoplasmic Sperm Injection (ICSI) Cycles: A Randomized Control Study. Unknown status NCT01760278 Phase 4 recombinant Follicle Stimulating Hormone (rFSH)
7 The Safety、Efficacy and Pharmacokinetics of Dexmedetomidine Administered Through Different Routes in Pediatric Unknown status NCT03337581 Phase 4 Dexmedetomidine
8 Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain: A Prospective Randomized Double-blind Placebo-controlled Crossover Study Unknown status NCT00404417 Phase 4 Botulinum Toxin A / Placebo;Botulinum Toxin A / Botulinum Toxin A;Placebo / Botulinum Toxin A;Placebo / Placebo
9 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
10 Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand Unknown status NCT01538940 Phase 4
11 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
12 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
13 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
14 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
15 Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring Unknown status NCT00841308 Phase 4
16 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
17 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
18 Contrast The Role of Microfibrillar Collagen Hemostat Flour（Avitene） And OK-432 （Sapylin）in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4 Avitene;Sapylin
19 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
20 Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
21 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
22 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
23 Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation. Unknown status NCT01216254 Phase 4
24 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
25 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
26 Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis Unknown status NCT02343562 Phase 4
27 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
28 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
29 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
30 Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury Unknown status NCT02530359 Phase 4 Pirfenidone extended release;Placebo equivalent
31 Evaluation of Post-Procedure Administration of Celecoxib Following Shoulder Surgery: A Randomized Controlled Study Unknown status NCT03305068 Phase 4 Celecoxib
32 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
33 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
34 Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Unknown status NCT03053739 Phase 4 Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo
35 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
36 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
37 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
38 Luteal Phase Support With Progesterone vs Estrogen and Progesterone on Pregnancy Rates in Ovarian Stimulation and Intrauterine Insemination Cycles: a Prospective Randomized Study Unknown status NCT01237535 Phase 4 Luteal support with progesterone only;Luteal support with estrogen + progesterone
39 Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes. Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
40 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
41 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
42 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (Short Title: TITRATE) Unknown status NCT02361489 Phase 4
43 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
44 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
45 A Multicenter, Randomized, Open-label Control Study to Evaluate Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients Unknown status NCT03448744 Phase 4 Thymosin Alpha1;Entecavir
46 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
47 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
48 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
49 Analgesic Efficacy of Oral Dexketoprofen Trometamol/Tramadol Hydrochloride Versus Tramadol Hydrochloride/Paracetamol: a Randomised, Double-blind, Placebo and Active-controlled, Parallel Group Study in Moderate to Severe Acute Pain After Removal of Impacted Lower Third Molar (Dexketoprofen Analgesic eVolution wIth tramaDol- DAVID Study) Unknown status NCT02777970 Phase 4 Tramadol Hydrochloride/Dexketoprofen Trometamol;Tramadol Hydrochloride/Paracetamol;Placebo
50 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride

Search NIH Clinical Center for Rhabdomyosarcoma 2

Cochrane evidence based reviews: rhabdomyosarcoma, alveolar

Sources

Genetic Tests for Rhabdomyosarcoma 2

About this section

Genetic tests related to Rhabdomyosarcoma 2:

# Genetic test Affiliating Genes
1 Alveolar Rhabdomyosarcoma (disease) 29 FOXO1 PAX3 PAX7
Sources

Anatomical Context for Rhabdomyosarcoma 2

About this section

MalaCards organs/tissues related to Rhabdomyosarcoma 2:

40
Breast, Lung, Prostate, Testes, Bone, Brain, Heart
Sources

Publications for Rhabdomyosarcoma 2

About this section

Articles related to Rhabdomyosarcoma 2:

(show top 50) (show all 1036)
# Title Authors PMID Year
1
Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. 61 56 54
8643596 1996
2
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. 54 61 56
8275086 1993
3
Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. 54 56 61
8098985 1993
4
Clinical utility gene card for: Alveolar rhabdomyosarcoma. 6 61
21829230 2012
5
Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? 61 56
11556833 2001
6
Localization of the t(2;13) breakpoint of alveolar rhabdomyosarcoma on a physical map of chromosome 2. 61 56
1505949 1992
7
Chromosomal sublocalization of the 2;13 translocation breakpoint in alveolar rhabdomyosarcoma. 61 56
1382566 1992
8
Localization of the rhabdomyosarcoma t(2;13) breakpoint on a physical map of chromosome 13. 61 56
1783402 1991
9
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. 56
12368906 2002
10
Chromosomal analysis of sixteen human rhabdomyosarcomas. 56
3338090 1988
11
Translocation 2;8 in a congenital rhabdomyosarcoma. 56
3342389 1988
12
A specific chromosomal abnormality in rhabdomyosarcoma. 56
3691179 1987
13
MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. 54 61
19707204 2009
14
The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma. 61 54
19704258 2009
15
Structural basis for DNA recognition by the human PAX3 homeodomain. 54 61
19199574 2009
16
Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. 61 54
18386058 2008
17
Adult cutaneous alveolar rhabdomyosarcoma on the face diagnosed by the expression of PAX3-FKHR gene fusion transcripts. 61 54
18705836 2008
18
Rhabdomyosarcoma an ubiquitous pediatric tumour. 54 61
18727437 2008
19
Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. 54 61
18414034 2008
20
[Diagnosis of micrometastases of alveolar rhabdomyosarcoma]. 54 61
18540440 2008
21
Comparison of the proximal promoter regions of the PAX3 and PAX7 genes. 54 61
17954266 2007
22
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. 61 54
16140913 2005
23
Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. 54 61
15313887 2004
24
Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. 61 54
15184910 2004
25
The MYCN oncoprotein as a drug development target. 61 54
12880971 2003
26
Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. 61 54
11863357 2002
27
Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. 61 54
11735247 2001
28
Regulating the neoplastic phenotype using engineered transcriptional repressors. 54 61
11164187 2001
29
Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. 61 54
10700864 2000
30
A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma. 54 61
10616906 1999
31
PAX3 gene structure, alternative splicing and evolution. 61 54
10521655 1999
32
PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. 54 61
10439042 1999
33
Expression of WT1 in pediatric small cell tumors: report of two cases with a possible mesothelial origin. 61 54
9841704 1999
34
The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. 61 54
9858583 1999
35
Normal and rearranged PAX3 expression in human rhabdomyosarcoma. 61 54
9546061 1998
36
Chromosomal translocations involving paired box transcription factors in human cancer. 54 61
9570138 1997
37
The genomic organization and the full coding region of the human PAX7 gene. 61 54
9339373 1997
38
Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines. 61 54
9294613 1997
39
[Pathologic diagnosis on bone and soft tissue tumors by molecular biological methods]. 54 61
9256013 1997
40
Expression of PAX3 in Ewing's sarcoma family of tumors. 61 54
9169092 1997
41
Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. 54 61
8889501 1996
42
Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. 54 61
8875708 1996
43
Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. 61 54
9052994 1996
44
MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). 61 54
8751388 1996
45
Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. 61 54
8634710 1995
46
The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. 54 61
7630639 1995
47
Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. 61 54
7624119 1995
48
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. 54 61
8083365 1994
49
Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. 54 61
8221646 1993
50
Orbital rhabdomyosarcoma. Immunohistochemical studies of seven cases. 54 61
2119961 1990
Sources

Variations for Rhabdomyosarcoma 2

About this section

ClinVar genetic disease variations for Rhabdomyosarcoma 2:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PAX7 NM_001135254.2(PAX7):c.220C>T (p.Arg74Ter)SNV Likely pathogenic 689508 1:18960931-18960931 1:18634437-18634437
2 PAX3 NM_181458.4(PAX3):c.580G>A (p.Glu194Lys)SNV Conflicting interpretations of pathogenicity 504786 rs148454691 2:223158892-223158892 2:222294173-222294173
3 PAX3 NM_181458.4(PAX3):c.540C>G (p.Ser180Arg)SNV Uncertain significance 504788 rs200679164 2:223158932-223158932 2:222294213-222294213
4 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg)SNV Uncertain significance 141928 rs371085910 5:112111352-112111352 5:112775655-112775655

Cosmic variations for Rhabdomyosarcoma 2:

9 (show top 50) (show all 679)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87906219 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.728T>C p.M243T 17:7674235-7674235 8
2 COSM88149182 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.668C>G p.P223R 17:7674863-7674863 8
3 COSM87949760 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
4 COSM88120884 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.739A>G p.N247D 17:7674224-7674224 8
5 COSM87911460 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.961A>T p.K321* 17:7673567-7673567 8
6 COSM87900604 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.637C>T p.R213* 17:7674894-7674894 8
7 COSM87898463 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.733G>T p.G245C 17:7674230-7674230 8
8 COSM88205650 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.611A>G p.E204G 17:7674920-7674920 8
9 COSM87898578 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.733G>A p.G245S 17:7674230-7674230 8
10 COSM87897745 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 8
11 COSM87897839 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.701A>G p.Y234C 17:7674262-7674262 8
12 COSM87898351 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.743G>A p.R248Q 17:7674220-7674220 8
13 COSM88094731 SOX9 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.76A>G p.M26V 17:72121467-72121467 8
14 COSM84133785 RICTOR soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.2898-1G>T p.? 5:38952426-38952426 8
15 COSM97041246 PTPRT soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.2277G>T p.Q759H 20:42248779-42248779 8
16 COSM146438832 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.214G>A p.A72T 12:112450394-112450394 8
17 COSM146438781 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.226G>C p.E76Q 12:112450406-112450406 8
18 COSM146439443 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1520G>T p.G507V 12:112489084-112489084 8
19 COSM146438825 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.205G>A p.E69K 12:112450385-112450385 8
20 COSM90839845 PTCH1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.208G>A p.A70T 9:95506593-95506593 8
21 COSM90587293 POLE soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5975G>C p.C1992S 12:132634215-132634215 8
22 COSM96437477 PIK3CG soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.2638G>A p.E880K 7:106883041-106883041 8
23 COSM87132301 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.1624G>A p.E542K 3:179218294-179218294 8
24 COSM87132544 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.1636C>A p.Q546K 3:179218306-179218306 8
25 COSM87132245 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3140A>G p.H1047R 3:179234297-179234297 8
26 COSM87132308 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1633G>A p.E545K 3:179218303-179218303 8
27 COSM88818803 PDGFRA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3195G>C p.E1065D 4:54295197-54295197 8
28 COSM97687376 NTRK3 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.492C>A p.C164* 15:88137534-88137534 8
29 COSM97107326 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.181C>A p.Q61K 1:114713909-114713909 8
30 COSM97107379 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>A p.G12D 1:114716126-114716126 8
31 COSM97107772 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 1:114716124-114716124 8
32 COSM97107813 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>A p.G12S 1:114716127-114716127 8
33 COSM97107359 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.182A>G p.Q61R 1:114713908-114713908 8
34 COSM97107717 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.38G>T p.G13V 1:114716123-114716123 8
35 COSM97107724 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 1:114716127-114716127 8
36 COSM87643288 NOTCH1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3277T>C p.Y1093H 9:136508280-136508280 8
37 COSM93680412 NF1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.7870G>C p.A2624P 17:31357269-31357269 8
38 COSM84820183 MYOD1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.365T>G p.L122R 11:17720147-17720147 8
39 COSM101727756 MAP3K1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1337G>A p.C446Y 5:56871945-56871945 8
40 COSM87804028 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.38G>A p.G13D 12:25245347-25245347 8
41 COSM87804083 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>C p.G12A 12:25245350-25245350 8
42 COSM87808527 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.182A>T p.Q61L 12:25227342-25227342 8
43 COSM87690443 KMT2D soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1291G>T p.E431* 12:49052392-49052392 8
44 COSM102156541 KDM6A soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.493C>T p.R165* 23:45020659-45020659 8
45 COSM112988832 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 11:534286-534286 8
46 COSM112988997 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 11:534289-534289 8
47 COSM112989371 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>A p.G12S 11:534289-534289 8
48 COSM112988917 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>T p.G12V 11:534288-534288 8
49 COSM98439571 GATA1 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.1099C>A p.L367M 23:48794021-48794021 8
50 COSM107501436 FGFR1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1704G>T p.M568I 8:38417358-38417358 8

Copy number variations for Rhabdomyosarcoma 2 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25460 1 18957499 19075360 Amplification PAX7 Alveolar rhabdomyosarcoma
2 76221 13 28900000 50900000 Amplification FOXO1A Alveolar rhabdomyosarcoma
3 141698 2 215300000 221500000 Amplification PAX3 Alveolar rhabdomyosarcoma
Sources

Expression for Rhabdomyosarcoma 2

About this section
Search GEO for disease gene expression data for Rhabdomyosarcoma 2.
Sources

Pathways for Rhabdomyosarcoma 2

About this section

Pathways related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.7 RB1 MDM2 IGF1R FOXO1 CDK4
2
Pathways in cancer 36
12.57 RB1 MDM2 IGF1R FOXO1 CDK4 ALK
3
Glioma 36
Show member pathways
 12.4 RB1 MDM2 IGF1R FOXO1 CDK4 ALK
4
MAPK Signaling: Mitogens 64
Show member pathways
 11.99 RB1 MDM2 IGF1R FOXO1 CDK4
5
Cellular senescence (KEGG) 36
11.95 RB1 MDM2 FOXO1 CDK4
6
Integrated Breast Cancer Pathway 1
11.92 RB1 MDM2 FOXO1 CDK4
7
Senescence and Autophagy in Cancer 1
11.78 RB1 MDM2 IGF1R
8
Androgen receptor signaling pathway 1
11.68 RB1 MDM2 FOXO1
9
Retinoblastoma (RB) in Cancer 1
11.66 RB1 MDM2 CDK4
10
Glioblastoma Multiforme 63
11.6 RB1 MDM2 IGF1R FOXO1 CDK4
11
Regulation of nuclear SMAD2/3 signaling 1
11.59 MYOD1 FOXO1 CDK4
12
Bladder cancer 36 1
11.55 RB1 MDM2 CDK4
13
Transcriptional misregulation in cancer 36
11.51 WT1 PAX7 PAX3 MYCN MDM2 IGF1R
14
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.5 RB1 IGF1R CDK4
15
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.33 PAX7 PAX3 MYOG MYOD1 DES
16
Integrated Cancer Pathway 1
11.32 RB1 MDM2 CDK4
17
Regulation of retinoblastoma protein 1
11.31 RB1 PAX3 MYOD1 MDM2
18
ID signaling pathway 1
10.77 RB1 MYOD1
Sources

GO Terms for Rhabdomyosarcoma 2

About this section

Cellular components related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.43 PAX7 PAX3 MYOG MYOD1 MYCN FOXO1
2 transcription factor complex GO:0005667 8.92 RB1 MYOG MYOD1 CDK4

Biological processes related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 WT1 RB1 PAX7 PAX3 MYOG MYOD1
2 negative regulation of apoptotic process GO:0043066 9.96 WT1 PAX7 MDM2 IGF1R FOXO1
3 regulation of transcription, DNA-templated GO:0006355 9.91 WT1 RB1 PAX7 PAX3 MYOG MYOD1
4 heart development GO:0007507 9.85 WT1 TH MDM2 MB
5 cellular response to growth factor stimulus GO:0071363 9.71 TH MYOG MDM2
6 skeletal muscle tissue development GO:0007519 9.67 PAX7 MYOG MYOD1
7 skeletal muscle cell differentiation GO:0035914 9.61 RB1 MYOG MYOD1
8 myotube differentiation GO:0014902 9.57 MYOG MYOD1
9 cellular response to alkaloid GO:0071312 9.52 TH MDM2
10 positive regulation of skeletal muscle fiber development GO:0048743 9.51 MYOG MYOD1
11 positive regulation of muscle cell differentiation GO:0051149 9.5 MYOG MYOD1 MDM2
12 muscle cell fate commitment GO:0042693 9.48 MYOG MYOD1
13 enucleate erythrocyte differentiation GO:0043353 9.46 RB1 MB
14 muscle organ development GO:0007517 9.46 PAX7 PAX3 MYOG MYOD1
15 response to ether GO:0045472 9.4 TH MDM2
16 positive regulation of transcription, DNA-templated GO:0045893 9.17 WT1 RB1 PAX3 MYOG MYOD1 MYCN
17 myoblast differentiation GO:0045445 9.13 RB1 MYOG MYOD1

Molecular functions related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.67 RB1 MYOD1 MDM2 FOXO1
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.65 WT1 MYOG MYOD1 MYCN FOXO1
3 sequence-specific DNA binding GO:0043565 9.63 WT1 PAX7 PAX3 MYOG MYOD1 FOXO1
4 proximal promoter sequence-specific DNA binding GO:0000987 9.5 RB1 MYOG MYOD1
5 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.5 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
6 DNA-binding transcription factor activity GO:0003700 9.23 WT1 RB1 PAX7 PAX3 MYOG MYOD1
Sources

Sources for Rhabdomyosarcoma 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....